Ngm Biopharmaceuticals Inc
NASDAQ:NGM 4:00:00 PM EDT
Market Cap (Intraday) | 141.32M |
Current PE | N/A |
Forward PE | N/A |
2yr Forward PE | N/A |
10-Day MA | $1.57 |
50-Day MA | $1.52 |
200-Day MA | $1.58 |
Ngm Biopharmaceuticals Inc Stock, NASDAQ:NGM
333 Oyster Point Boulevard, South San Francisco, California 94080-7014
United States of America
Phone: +1.650.243.5555
Number of Employees: 138
Description
NGM Biopharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel biologic drug candidates. Its programs include NGM707 and pembrolizumab for treating metastatic solid tumors, Aldafermin for primary sclerosing cholangitis, and NGM120 for hyperemesis gravidarum. The company was founded by Jin Long Chen on December 20, 2007 and is headquartered in South San Francisco, CA.